Customer Center
Login | Register

Investor Relations

Investor Relations

Upcoming Event
More events are coming soon.

Stock Information

More >>

Recent News

More >>
Date Title  
Toggle Summary Luminex Receives FDA Emergency Use Authorization for ARIES® SARS-CoV-2 Assay to Detect Virus Responsible for COVID-19 Disease
Luminex is now able to provide SARS-CoV-2 diagnostic tests for both high-complexity, high-throughput reference labs and moderate complexity, sample-to-answer testing facilities AUSTIN, Texas , April 6, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug
Toggle Summary Luminex Receives BARDA Contract to Support Development of Second, Rapid SARS-CoV-2 Test
- Follows BARDA Contract and EUA for NxTAG® CoV Extended Panel last week - ARIES® SARS-CoV-2 Assay will be submitted for EUA later this week AUSTIN, Texas , March 31, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received $642,450 in funding from the Biomedical